Lobbying disclosures · Lobbying report
ALNY: third_quarter 2026 lobbying report
Issues related to the implementation of the Inflation Reduction Act. Home infusion policy. Issues related to MFN drug pricing. Issues relating to supply chain tariffs. Implementation of The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (PL 116-94). Drug Pricing. FY2026 Labor HHS appropriations. Genetically targeted technologies. Policies related to medical innovation.
Follow ALNY- Became public
- Oct 19, 2026, 8:22 AM EDT
- Event / period date
- Not stated
- Collected
- Nov 11, 2026, 7:09 AM EST
Why this is connected
Exact legal-name match: ALNYLAM PHARMACEUTICALS, INC. (https://www.sec.gov/Archives/edgar/data/1178670/).
Reported lobbying amounts
Income: $60,000.00
These are different reporting measures. They are not added together or treated as spending on one particular bill.
Source evidence
Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/06b8043b-fdcd-40f7-878c-3206cc573869/","filing_uuid":"06b8043b-fdcd-40f7-878c-3206cc573869","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/06b8043b-fdcd-40f7-878c-3206cc573869/print/","filing_document_content_type":"text/html","income":"60000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Beth Anne Cole","dt_posted":"2026-10-19T08:22:02-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1201 New York Avenue, NW","registrant_address_2":"8th Floor","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20005","registrant":{"id":401103321,"url":"https://lda.gov/api/v1/registrants/401103321/","house_registrant_id":null,"name":"TODD STRATEGY GROUP","description":"​Government Affairs Consulting Firm.","address_1":"1201 New York Avenue, NW","address_2":"8th Floor","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20005","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"BETH ANNE COLE","contact_telephone":"+1 202-352-7761","dt_updated":"2026-07-30T17:35:40.053965-04:00"},"client":{"id":198563,"url":"https://lda.gov/api/v1/clients/198563/","client_id":176,"name":"ALNYLAM PHARMACEUTICALS, INC.","general_description":"Biopharmaceutical company","client_government_entity":false,"client_self_select":null,"state":"MA","state_display":"Massachusetts","country":"US","country_display":"United States of America","ppb_state":"MA","ppb_state_display":"Massachusetts","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-07-01"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues related to the implementation of the Inflation Reduction Act. Home infusion policy. Issues related to MFN drug pricing.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":69314,"prefix":null,"prefix_display":null,"first_name":"PAUL","nickname":null,"middle_name":null,"last_name":"EDATTEL","suffix":null,"suffix_display":null},"covered_position":"Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg","new":false},{"lobbyist":{"id":142860,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":"FLEMING","last_name":"COTTON","suffix":null,"suffix_display":null},"covered_position":"Staff Assistant, Legislative Correspondent, Legislative Assistant - U.S. Representative Brett Guthrie","new":false},{"lobbyist":{"id":144898,"prefix":null,"prefix_display":null,"first_name":"ERIC","nickname":null,"middle_name":null,"last_name":"BERGREN","suffix":null,"suffix_display":null},"covered_position":"Chief of Staff, Rep. Brett Guthrie; Staff Assistant, Legislative Correspondent, Legislative Assistant, Senior Legislative Assistant, Legislative Director, Chief of Staff - Rep. Ron Lewis; Intern, Rep. Bill Baker","new":false},{"lobbyist":{"id":152870,"prefix":"mr","prefix_display":"MR.","first_name":"NICOLAS","nickname":null,"middle_name":null,"last_name":"MAGALLANES","suffix":null,"suffix_display":null},"covered_position":"Senior Advisor - House Republican Conference; Policy Advisor/Professional Staff Member - U.S. Representative Lee Terry/Energy and Commerce Committee; Legislative Correspondent/Legislative Aide - U.S. Senator Lamar Alexander","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Issues relating to supply chain tariffs.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":69314,"prefix":null,"prefix_display":null,"first_name":"PAUL","nickname":null,"middle_name":null,"last_name":"EDATTEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142860,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":"FLEMING","last_name":"COTTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144898,"prefix":null,"prefix_display":null,"first_name":"ERIC","nickname":null,"middle_name":null,"last_name":"BERGREN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152870,"prefix":"mr","prefix_display":"MR.","first_name":"NICOLAS","nickname":null,"middle_name":null,"last_name":"MAGALLANES","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Implementation of The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (PL 116-94). Drug Pricing. FY2026 Labor HHS appropriations. Genetically targeted technologies. Policies related to medical innovation.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":69314,"prefix":null,"prefix_display":null,"first_name":"PAUL","nickname":null,"middle_name":null,"last_name":"EDATTEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142860,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":"FLEMING","last_name":"COTTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144898,"prefix":null,"prefix_display":null,"first_name":"ERIC","nickname":null,"middle_name":null,"last_name":"BERGREN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152870,"prefix":"mr","prefix_display":"MR.","first_name":"NICOLAS","nickname":null,"middle_name":null,"last_name":"MAGALLANES","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}Congressional trading in ALNY
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Sep 9, 2026$1K–$15K
Sen. Cory A. Booker (D-NJ)
Sold (full) Alnylam Pharmaceuticals ALNY
$1K–$15K · Traded Aug 11, 2026 · disclosed Sep 9, 2026 · Spouse
- Jun 22, 2025$15K–$50K
Rep. Jefferson Shreve (R-IN-6)
Sold Alnylam Pharmaceuticals ALNY
$15K–$50K · Traded May 12, 2025 · disclosed Jun 22, 2025
- Feb 15, 2024$1K–$15K
Rep. Josh Gottheimer (D-NJ-5)
Sold Alnylam Pharmaceuticals ALNY
$1K–$15K · Traded Jan 29, 2024 · disclosed Feb 15, 2024 · Joint
- Feb 15, 2024$1K–$15K
Rep. Josh Gottheimer (D-NJ-5)
Bought Alnylam Pharmaceuticals ALNY
$1K–$15K · Traded Jan 11, 2024 · disclosed Feb 15, 2024 · Joint
- Jan 7, 2024$1K–$15K
Rep. Josh Gottheimer (D-NJ-5)
Sold Alnylam Pharmaceuticals ALNY
$1K–$15K · Traded Dec 11, 2023 · disclosed Jan 7, 2024 · Joint
- Apr 17, 2023$15K–$50K
Rep. Daniel S. Goldman (D-NY-10)
Bought Alnylam Pharmaceuticals ALNY
$15K–$50K · Traded Mar 6, 2023 · disclosed Apr 17, 2023
- Feb 24, 2023$15K–$50K
Rep. Daniel S. Goldman (D-NY-10)
Sold Alnylam Pharmaceuticals ALNY
$15K–$50K · Traded Jan 31, 2023 · disclosed Feb 24, 2023
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.